Abound Bio

Abound Bio is a biotechnology company focused on the discovery and development of novel antibody-based therapeutics using its proprietary VH domain library platform. The company's technology leverages large, diverse libraries of human antibody fragments to engineer multi-specific and multi-valent biologics with superior potency and modularity. Founded by pioneers in the field of antibody engineering, Abound Bio targets a range of indications in oncology and infectious diseases. In January 2024, the company was acquired by Orna Therapeutics to combine its protein engineering expertise with Orna's circular RNA (oRNA) platform. This integration aims to accelerate the development of in situ CAR (isCAR) therapies and other advanced RNA-based medicines.